Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
$1.24
-2.4%
$1.29
$1.05
$10.16
$38.87M1.65270,335 shs122,862 shs
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$1.51
$1.49
$0.20
$2.63
$10.35M1.58352,864 shs120,938 shs
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
$11.16
+5.3%
$9.39
$2.31
$13.70
$39.17M-0.5957,220 shs47,809 shs
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$3.22
+9.2%
$3.05
$1.75
$4.97
$44.53M0.7269,926 shs171,951 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
0.00%-1.59%-6.06%+3.33%-83.88%
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.00%0.00%0.00%0.00%+3.78%
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.00%+4.10%+18.58%+12.73%+176.24%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
0.00%+12.20%-6.40%+18.38%+321,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
2.5656 of 5 stars
3.55.00.00.00.01.70.6
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
3.00
Buy$17.711,328.57% Upside
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.00
N/AN/AN/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.00
N/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
3.00
Buy$12.00272.67% Upside

Current Analyst Ratings Breakdown

Latest AGRX, ACRV, COEP, and GRCE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
5/15/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.00
(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/A$5.68 per shareN/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$19.98M0.52N/AN/A($5.51) per share-0.27
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/AN/AN/AN/A$1.61 per shareN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/A$4.86 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$80.56M-$2.22N/AN/AN/AN/A-44.66%-40.94%8/12/2025 (Estimated)
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
-$14.47M-$3.65N/AN/A-36.24%N/A-147.37%N/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
-$10.88M-$5.80N/AN/AN/A-282.39%-127.23%N/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$9.57M-$0.89N/AN/AN/AN/A-19.45%-16.99%N/A

Latest AGRX, ACRV, COEP, and GRCE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$0.57N/AN/AN/AN/AN/A
6/20/2025Q4 2025
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.23-$0.21+$0.02$0.01N/AN/A
5/14/2025Q1 2025
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/A-$1.11N/A-$1.11N/AN/A
5/13/2025Q1 2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$0.57-$0.51+$0.06-$0.51N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/AN/A
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/AN/AN/AN/AN/A
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
N/AN/AN/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/A
11.17
11.17
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/A
0.56
0.38
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
0.02
0.82
0.82
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A
11.77
11.77

Institutional Ownership

CompanyInstitutional Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
71.62%
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
10.92%
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
13.88%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
6.08%

Insider Ownership

CompanyInsider Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
8.50%
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.50%
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
24.25%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
11.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
5831.35 million28.69 millionNot Optionable
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
306.86 million6.82 millionNot Optionable
Coeptis Therapeutics Holdings, Inc. stock logo
COEP
Coeptis Therapeutics
23.51 million2.66 millionNot Optionable
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A13.83 million12.29 millionN/A

Recent News About These Companies

GRCE: NDA Submitted
GRCE: Progress Report
GRCE Grace Therapeutics, Inc.
New Biotech Stocks at Investorideas.com
GRCE: STRIVE-ON Results Reported
Grace Therapeutics reports Q3 EPS (36c), consensus (46c)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acrivon Therapeutics stock logo

Acrivon Therapeutics NASDAQ:ACRV

$1.24 -0.03 (-2.36%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$1.25 +0.01 (+1.21%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Agile Therapeutics stock logo

Agile Therapeutics NASDAQ:AGRX

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Coeptis Therapeutics stock logo

Coeptis Therapeutics NASDAQ:COEP

$11.16 +0.56 (+5.28%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$11.20 +0.04 (+0.36%)
As of 08/8/2025 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Grace Therapeutics stock logo

Grace Therapeutics NASDAQ:GRCE

$3.22 +0.27 (+9.15%)
As of 08/8/2025 04:00 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.